Free Trial
NASDAQ:LNSR

LENSAR Q3 2025 Earnings Report

LENSAR logo
$5.78 +0.14 (+2.48%)
Closing price 05/11/2026 04:00 PM Eastern
Extended Trading
$5.74 -0.04 (-0.62%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LENSAR EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A

LENSAR Revenue Results

Actual Revenue
$14.32 million
Expected Revenue
$17.75 million
Beat/Miss
Missed by -$3.43 million
YoY Revenue Growth
N/A

LENSAR Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
7:00AM ET

LENSAR Earnings Headlines

Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2025 - says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. When the Fed cut rates in 2020, his readers had a chance at 62% gains. A 2022 rate-hike signal produced 117% in under a month. Now Benedict has identified the single ticker he believes will be at the center of the coming money flows - and he's revealing it free before May 15.tc pixel
See More LENSAR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email.

About LENSAR

LENSAR (NASDAQ:LNSR), headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency.

Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.

View LENSAR Profile